1-(oxiran-2-ylmethyl)-1H-indole | 150389-86-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(oxiran-2-ylmethyl)-1H-indole
• 英文别名: 1-(2-oxiranylmethyl)-1H-indole；1-(2,3-epoxypropyl)-1H-indole；N-indolylmethyloxirane；1-oxiranylmethyl-indole；1-N-Glycidyl-indole；1-N-Indolyl-2,3-epoxypropan；1-N-glycidylindole；1-(oxiran-2-ylmethyl)indole
• CAS: 150389-86-9；32119-62-3
• 化学式: C₁₁H₁₁NO
• 分子量: 173.214
• InChiKey: LDCGJHXNODDHOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  17.5
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(oxiran-2-ylmethyl)-1H-indole 在 碳酸氢钠 作用下， 以 乙醇 、 水 为溶剂， 反应 15.5h， 生成 3,3'-trisulfanediylbis(1-(1H-indol-1-yl)propan-2-ol)
  参考文献：
  名称：

  Protected bis(hydroxyorganyl) polysulfides as modifiers of Li/S battery electrolyte

  摘要：

  The protected bis(hydroxyorganyl) polysulfides synthesized have been tested as modifiers of electrolyte of lithium-sulfur rechargeable batteries. The best result (35% increase of the battery capacity at the 50th cycle) was attained using 5 wt.% of 2,2,12,12-tetramethyl-4,10-diphenyl-3,11-dioxa-6,7,8-trithia-2,12-disilatridecane. Bis(hydroxyorganyl) polysulfides protected at the hydroxyl group have been synthesized for the first time by the reaction of oxiranes with sodium polysulfide (ethanol. NaHCO(3), 12h, 20-25 degrees C) in yield 21-87%. For the hydroxyl protection in the hydroxy polysulfides, the acetal, tri(methyl)silyloxy or tri(ethoxy)silyl protecting groups were employed. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.electacta.2010.11.064
• 作为产物：
  描述：

  1-Chloro-3-indol-1-yl-propan-2-ol 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 15.0h， 生成 1-(oxiran-2-ylmethyl)-1H-indole
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of 5-dialkylaminomethyl-2-amino-2-oxazolines as H1-antagonists

  摘要：

  摘要：从相应的二烷基胺中，通过两步合成了新的5-二烷基氨甲基-2-氨基-2-噁唑啉。它们在体外被评估为H1-拮抗剂。化合物1c、1d和1j显著拮抗了组织胺诱导的豚鼠气管收缩，使组织胺的浓度-反应曲线向右移。化合物1f，5-[(4-苄基-1-哌啶基)甲基]-2-氨基-2-噁唑啉，导致乙酰胆碱Emax（对乙酰胆碱10^-3 M的最大反应）增加，并使浓度-反应曲线向左移。该化合物对组织胺诱导的收缩无影响，排除了非选择性增强收缩机制的可能性。初步的结构活性结果部分基于理化结果报告。

  DOI：

  10.1211/0022357011776315

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Trifluoromethylthiolation of epoxides with AgSCF3: A new access to vinyl trifluoromethyl thioethers
  作者：Hui-Ting Chen、Yangen Huang、Feng-Ling Qing、Xiu-Hua Xu

  DOI：10.1016/j.tetlet.2020.151628

  日期：2020.3

  An unexpected synthesis of vinyl trifluoromethyl thioethers from epoxides has been described. Treatment of epoxides with AgSCF3 in the presence of n-Bu4NI and KI in toluene afforded various vinyl trifluoromethyl thioethers in moderate to good yields. The use of easily available substrates and tolerance of wide functional groups are the notable advantages of this protocol.

  已经描述了由环氧化物意外地合成乙烯基三氟甲基硫醚的方法。在甲苯中存在n-Bu 4 NI和KI的情况下，用AgSCF 3处理环氧化物，得到各种乙烯基三氟甲基硫醚，产率中等至良好。易于使用的底物的使用和宽泛的官能团的耐受性是该协议的显着优势。
• Modulators of ATP-binding cassette transporters
  申请人：Hadida Ruah S. Sara

  公开号：US20070244159A1

  公开（公告）日：2007-10-18

  Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物，可用作调节ATP结合盒（“ABC”）转运蛋白或其片段的工具，包括囊性纤维化跨膜传导调节蛋白（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• Synthesis of 9-substituted 2,3,4,9-tetrahydro-1H-carbazole derivatives and evaluation of their anti-prion activity in TSE-infected cells
  作者：Tsutomu Kimura、Junji Hosokawa-Muto、Kenji Asami、Toshiaki Murai、Kazuo Kuwata

  DOI：10.1016/j.ejmech.2011.08.039

  日期：2011.11

  a variety of GJP14 derivatives were prepared using pyrrole derivatives, (haloalkyl)oxiranes, and amines, and their anti-prion activity was evaluated in TSE-infected cells. It was found that the tricyclic aromatic ring, a hydroxy group at the 2-position and an amino group at the 3-position of the N-propyl group were the basic requirements for anti-prion activity. The derivatives bearing an N-ortho-halobenzyl

  2,3,4,9-四氢-9- [2-羟基-3-（1-哌啶基）丙基] -6-甲基-1 H-咔唑-1-酮（GJP14）是一种新型的抗-病毒化合物，我们之前是通过计算机筛选和细胞分析发现的。在这项研究中，使用吡咯衍生物，（卤代烷基）氧杂环丁烷和胺制备了多种GJP14衍生物，并在TSE感染的细胞中评估了它们的抗-病毒活性。发现三环芳环，N-丙基的2-位羟基和3-位的氨基是抗-病毒活性的基本要求。衍生物轴承的ñ -邻-卤代苄基具有更高的活性，最有效的衍生物是原始的先导化合物GJP14的8倍。